Novo has “gone shopping” to fill pipeline gaps, with a focus on obesity and diabetes, plus an expansion in blood and endocrine disorders, liver diseases and cardiovascular conditions.
Aside from its manufacturing and distribution footprint, ITM Isotope Technologies Munich will give Telix Pharmaceuticals the late-stage ITM-11, being developed for gastroenteropancreatic ...
Delivering therapeutics directly to tumors, as in the case of Replimune’s recently approved Tudriqev and Amgen’s Imlygic, ...
Novartis Cosentyx receives positive CHMP opinion for expanded use in childhood arthritic conditions. [Press release].
"This year's Late-Breaking Science program reflects the pace of innovation transforming heart failure care," said Jennifer ...
The peer-reviewed paper describes the scientific and translational foundation for sasineprocel (ANPD001), Aspen’s ...
Silo’s biopharmaceutical intellectual property portfolio currently holds numerous issued and allowed patents. About Silo ...
As molecule complexity rises, advanced cell line development platforms are giving biopharma companies new tools to overcome ...
Newly permanent CBER and CDER directors Karim Mikhail and Michael Davis are widely expected to continue the FDA’s efforts toward an adaptive framework for rare disease therapies. If approved by the ...
The presentation will provide an overview of the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) ...
This announcement describes preparation of a demonstration and does not constitute a commercial contract award. Medical Care ...
FAYUVI™ is the first FDA-approved gene therapy manufactured using the Andelyn AAV Curator® Platform process. Its commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results